1. Home
  2. DCBO vs WVE Comparison

DCBO vs WVE Comparison

Compare DCBO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCBO
  • WVE
  • Stock Information
  • Founded
  • DCBO 2016
  • WVE 2012
  • Country
  • DCBO Canada
  • WVE Singapore
  • Employees
  • DCBO N/A
  • WVE N/A
  • Industry
  • DCBO
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • DCBO
  • WVE Health Care
  • Exchange
  • DCBO Nasdaq
  • WVE Nasdaq
  • Market Cap
  • DCBO 893.7M
  • WVE 915.6M
  • IPO Year
  • DCBO 2020
  • WVE 2015
  • Fundamental
  • Price
  • DCBO $31.18
  • WVE $9.93
  • Analyst Decision
  • DCBO Strong Buy
  • WVE Strong Buy
  • Analyst Count
  • DCBO 5
  • WVE 16
  • Target Price
  • DCBO $42.20
  • WVE $20.00
  • AVG Volume (30 Days)
  • DCBO 100.6K
  • WVE 1.7M
  • Earning Date
  • DCBO 08-08-2025
  • WVE 07-30-2025
  • Dividend Yield
  • DCBO N/A
  • WVE N/A
  • EPS Growth
  • DCBO 33.51
  • WVE N/A
  • EPS
  • DCBO 0.69
  • WVE N/A
  • Revenue
  • DCBO $230,502,000.00
  • WVE $93,946,000.00
  • Revenue This Year
  • DCBO $13.02
  • WVE N/A
  • Revenue Next Year
  • DCBO $8.37
  • WVE $10.02
  • P/E Ratio
  • DCBO $44.95
  • WVE N/A
  • Revenue Growth
  • DCBO 15.11
  • WVE N/A
  • 52 Week Low
  • DCBO $25.50
  • WVE $5.04
  • 52 Week High
  • DCBO $53.86
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • DCBO 52.69
  • WVE 65.83
  • Support Level
  • DCBO $29.45
  • WVE $9.26
  • Resistance Level
  • DCBO $31.25
  • WVE $10.58
  • Average True Range (ATR)
  • DCBO 0.95
  • WVE 0.50
  • MACD
  • DCBO -0.10
  • WVE 0.05
  • Stochastic Oscillator
  • DCBO 44.12
  • WVE 76.62

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: